Global Hemoperfusion Market Growth 2026-2032
Description
The global Hemoperfusion market size is predicted to grow from US$ 468 million in 2025 to US$ 810 million in 2032; it is expected to grow at a CAGR of 8.9% from 2026 to 2032.
Hemoperfusion is a treatment technique in which large volumes of the patient's blood are passed over an adsorbent substance in order to remove toxic substances from the blood. Adsorption is a process in which molecules or particles of one substance are attracted to the surface of a solid material and held there. These solid materials are called sorbents.In 2025, global Hemoperfusion production reached approximately 7052 K Unit.
Hemoperfusion demand is driven first by clinical need in critical care where standard supportive therapies (ventilation, vasopressors, renal replacement therapy) don’t directly remove circulating toxins or inflammatory mediators. The core use-cases that pull adoption are: acute poisonings/drug intoxications (where removing protein-bound or lipophilic toxins can matter), liver failure and hyperbilirubinemia, and severe systemic inflammation (sepsis/septic shock, pancreatitis, certain post-surgical or trauma inflammatory states) where clinicians aim to reduce circulating cytokines/endotoxin burden. Growth is also supported by rising ICU volumes tied to aging populations and higher prevalence of multi-morbidity (cardiometabolic disease, chronic kidney disease), plus increasing recognition of “adjunctive blood purification” options in settings where mortality remains high despite best-practice bundles.
A second set of drivers is workflow and technology fit: hemoperfusion can be deployed as a stand-alone circuit or integrated with CRRT/ECMO platforms, allowing hospitals to add it without building an entirely new infrastructure. The market is pulled by single-use consumables (cartridges/columns) with predictable ordering patterns once protocols are established, and by product improvements such as higher adsorption capacity, better biocompatibility, lower clotting risk, and more consistent performance across patient conditions. Commercial adoption is strongly influenced by reimbursement coverage, local health-technology assessments, and hospital procurement economics (ICU length-of-stay impact, vasopressor days, dialysis days). Finally, evidence quality is a major gatekeeper: more positive real-world data, better patient-selection criteria, and clearer endpoints (hemodynamic stabilization, organ-support intensity, biomarker kinetics) tend to unlock broader uptake, while mixed trial outcomes can slow it or confine usage to specific indications and regions.
Gross profit margin (industry, short): hemoperfusion is typically a high–gross-margin consumables model (single-use cartridges plus accessories) once scale and yields are stable, because material costs are modest relative to clinical selling price and value is tied to outcomes and compatibility. In practice, margins vary widely by region and competitive intensity, but many established players target roughly ~50–70% gross margin.
LP Information, Inc. (LPI) ' newest research report, the “Hemoperfusion Industry Forecast” looks at past sales and reviews total world Hemoperfusion sales in 2025, providing a comprehensive analysis by region and market sector of projected Hemoperfusion sales for 2026 through 2032. With Hemoperfusion sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemoperfusion industry.
This Insight Report provides a comprehensive analysis of the global Hemoperfusion landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemoperfusion portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemoperfusion market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemoperfusion and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemoperfusion.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemoperfusion market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Activated Carbon Adsorption
Resin Adsorption
Segmentation by Feature:
Plasma Perfusion
Whole Blood Perfusion
Segmentation by Channel:
Direct Selling
Distribution
Segmentation by Application:
Hepatic Encephalopathy
Certain Autoimmune Diseases
Drug Overdose
Specific Intoxications
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Jianfan Biotech
Kangbei Medical
Foshan Boxin (Lily Medical)
Baxter
Asahi Kasei
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hemoperfusion market?
What factors are driving Hemoperfusion market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hemoperfusion market opportunities vary by end market size?
How does Hemoperfusion break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Hemoperfusion is a treatment technique in which large volumes of the patient's blood are passed over an adsorbent substance in order to remove toxic substances from the blood. Adsorption is a process in which molecules or particles of one substance are attracted to the surface of a solid material and held there. These solid materials are called sorbents.In 2025, global Hemoperfusion production reached approximately 7052 K Unit.
Hemoperfusion demand is driven first by clinical need in critical care where standard supportive therapies (ventilation, vasopressors, renal replacement therapy) don’t directly remove circulating toxins or inflammatory mediators. The core use-cases that pull adoption are: acute poisonings/drug intoxications (where removing protein-bound or lipophilic toxins can matter), liver failure and hyperbilirubinemia, and severe systemic inflammation (sepsis/septic shock, pancreatitis, certain post-surgical or trauma inflammatory states) where clinicians aim to reduce circulating cytokines/endotoxin burden. Growth is also supported by rising ICU volumes tied to aging populations and higher prevalence of multi-morbidity (cardiometabolic disease, chronic kidney disease), plus increasing recognition of “adjunctive blood purification” options in settings where mortality remains high despite best-practice bundles.
A second set of drivers is workflow and technology fit: hemoperfusion can be deployed as a stand-alone circuit or integrated with CRRT/ECMO platforms, allowing hospitals to add it without building an entirely new infrastructure. The market is pulled by single-use consumables (cartridges/columns) with predictable ordering patterns once protocols are established, and by product improvements such as higher adsorption capacity, better biocompatibility, lower clotting risk, and more consistent performance across patient conditions. Commercial adoption is strongly influenced by reimbursement coverage, local health-technology assessments, and hospital procurement economics (ICU length-of-stay impact, vasopressor days, dialysis days). Finally, evidence quality is a major gatekeeper: more positive real-world data, better patient-selection criteria, and clearer endpoints (hemodynamic stabilization, organ-support intensity, biomarker kinetics) tend to unlock broader uptake, while mixed trial outcomes can slow it or confine usage to specific indications and regions.
Gross profit margin (industry, short): hemoperfusion is typically a high–gross-margin consumables model (single-use cartridges plus accessories) once scale and yields are stable, because material costs are modest relative to clinical selling price and value is tied to outcomes and compatibility. In practice, margins vary widely by region and competitive intensity, but many established players target roughly ~50–70% gross margin.
LP Information, Inc. (LPI) ' newest research report, the “Hemoperfusion Industry Forecast” looks at past sales and reviews total world Hemoperfusion sales in 2025, providing a comprehensive analysis by region and market sector of projected Hemoperfusion sales for 2026 through 2032. With Hemoperfusion sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemoperfusion industry.
This Insight Report provides a comprehensive analysis of the global Hemoperfusion landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemoperfusion portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Hemoperfusion market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemoperfusion and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemoperfusion.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemoperfusion market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Activated Carbon Adsorption
Resin Adsorption
Segmentation by Feature:
Plasma Perfusion
Whole Blood Perfusion
Segmentation by Channel:
Direct Selling
Distribution
Segmentation by Application:
Hepatic Encephalopathy
Certain Autoimmune Diseases
Drug Overdose
Specific Intoxications
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Jianfan Biotech
Kangbei Medical
Foshan Boxin (Lily Medical)
Baxter
Asahi Kasei
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hemoperfusion market?
What factors are driving Hemoperfusion market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hemoperfusion market opportunities vary by end market size?
How does Hemoperfusion break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
84 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Hemoperfusion by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Hemoperfusion by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
